D. Boral Capital Initiates Coverage on Estrella Immunopharma (NASDAQ:ESLA)

Analysts at D. Boral Capital initiated coverage on shares of Estrella Immunopharma (NASDAQ:ESLA) in a note issued to investors on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $16.00 price target on the stock.

Estrella Immunopharma Trading Down 4.9 %

NASDAQ:ESLA opened at $1.37 on Tuesday. The firm has a market capitalization of $49.57 million, a PE ratio of -5.27 and a beta of 0.41. Estrella Immunopharma has a 52 week low of $0.63 and a 52 week high of $3.23. The stock has a 50 day moving average of $1.16 and a 200-day moving average of $1.10.

Institutional Investors Weigh In On Estrella Immunopharma

An institutional investor recently raised its position in Estrella Immunopharma stock. Geode Capital Management LLC grew its holdings in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) by 22.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 93,418 shares of the company’s stock after acquiring an additional 16,862 shares during the quarter. Geode Capital Management LLC owned about 0.26% of Estrella Immunopharma worth $106,000 as of its most recent SEC filing. 0.35% of the stock is owned by institutional investors.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.